April 17, 2026 · The American journal of psychiatry · DOI: 10.1176/appi.ajp.20250886

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia

Listen to this summary

The authors investigate the potential of targeting the cannabinoid CB1 receptor (CB1R) as a therapeutic strategy for treating schizophrenia, particularly in individuals with comorbid cannabis use. They review the relationship between the endocannabinoid system and schizophrenia, highlighting how cannabis exacerbates symptoms and affects prognosis. The paper aims to outline recent advances in understanding CB1R biology and pharmacology that could inform the development of effective treatments for schizophrenia.

Shih-Hsuan Ku, Sierra J Stringfield, Mary M Torregrossa, Robert A Sweet, Shinnyi Chou

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play